ClinicalTrials.gg
CompletedNCT02428608EV-006Updated Apr 24, 2019Results posted

Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006

A Phase 2 interventional study of DWP-450 (Botulinum purified neurotoxin, Type A) in Glabellar Frown Lines, sponsored by Evolus, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-24.

Sponsored by Evolus, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
570
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult subjects.

Read the detailed description

Up to five hundred and thirty (530) subjects will be enrolled and injected with the study drug DWP-450 over the course of the 365 day study.

Subjects with moderate-to-severe glabellar lines at maximum frown on the 4 point Glabellar Line Scale (GLS, 0=none, 1= mild, 2=moderate, 3=severe), as judged by the investigator, will be eligible for injection with DWP-450.

Subjects may receive up to a maximum of 4 treatments and will be followed for 365 days from initial treatment.

02

Conditions studied

  • Glabellar Frown Lines

Keywords

  • Glabellar Lines
  • Botulinum toxin, Type A
03

In context

Lead sponsor

Evolus, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be an adult 18 years of age and over
  • Subject is able to provide and comply with study instructions
  • Subject has moderate-to-severe glabellar lines on maximum frown as assessed by the investigator and subject using the GLS
  • Subject is willing and able to complete the entire course of the study

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with botulinum toxin of any serotype in any area within the last 6 months
  • Previous treatment with any facial aesthetic procedure (e.g. injection with fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months
  • Previous insertion of permanent material in the glabellar area
  • Planned treatment with botulinum toxin of any serotype in any other body region during the study period
  • Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area and the surrounding areas (including eye brow)
  • Energy based or cryo-therapy based treatment of facial muscles superior to the lateral canthus
  • Any other planned facial aesthetic procedure during the trial period, superior to the level of the lateral canthus (subjects can continue with their usual skin care routine)
  • Inability to substantially lessen glabellar frown lines even by physically spreading them apart
  • Marked facial asymmetry
  • Ptosis of eyelid and/or eyebrow, or history of eyelid and/or eyebrow ptosis
  • History of facial nerve palsy
  • Excessive dermatochalasis, deep dermal scarring, thick sebaceous skin
  • Any active infection in the area of the injection sites
  • Medical condition that may affect neuromuscular function (e.g., myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis)
  • Evidence of recent alcohol or drug abuse
  • Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study
  • Pregnant, nursing or sexually active female subjects who are of and who are not willing to use an acceptable form of
  • Known allergy or to botulinum toxin preparation
  • Participation in another interventional clinical study within the last 30 days
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
570 participants (actual)

Study arms

  • Experimental
    Botulinum toxin, Tyoe A

    DWP-450 (Botulinum toxin, Type A)

    Biological: DWP-450 (Botulinum purified neurotoxin, Type A)

Interventions

06

What researchers measure

Primary outcomes

  1. The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year

    The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365.

    Time frame: 365 days

Other outcomes

  1. Change From Baseline Glabellar Line Scale (GLS) Score at Rest and at Maximum Frown

    Proportion of subjects with an improvement of 1 point or more (i.e., ≥1 point responders) on the GLS at rest at end of study/early termination: by Investigator assessment

    Time frame: 365 days

07

Results

Posted Feb 5, 2019

Participant flow

Participant flow — Overall Study
MilestoneBotulinum Toxin, Tyoe A
Started570
Completed487
Not completed83
Withdrew: Pregnancy2
Withdrew: Lost to follow-up37
Withdrew: Withdrawal by subject2
Withdrew: Scheduling conflicts15
Withdrew: Moved away10
Withdrew: Death1
Withdrew: Various16

Outcome measures

PrimaryThe Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year

The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365.

Time frame:
365 days
Reported as:
Count of participants · Participants
The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year
ParticipantsBotulinum Toxin, Tyoe A
The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year235
Other pre-specifiedChange From Baseline Glabellar Line Scale (GLS) Score at Rest and at Maximum Frown

Proportion of subjects with an improvement of 1 point or more (i.e., ≥1 point responders) on the GLS at rest at end of study/early termination: by Investigator assessment

Time frame:
365 days
Reported as:
Count of participants · Participants
Change From Baseline Glabellar Line Scale (GLS) Score at Rest and at Maximum Frown
ParticipantsBotulinum Toxin, Type A
Change From Baseline Glabellar Line Scale (GLS) Score at Rest and at Maximum Frown355

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Botulinum Toxin, Type A—7/570 (1.2%)228/570 (40%)
Most frequent serious events
Most frequent serious events
EventBotulinum Toxin, Type A
Carotid artery stenosisNervous system disorders1/570
OverdoseInjury, poisoning and procedural complications1/570
Small intestinal obstructionGastrointestinal disorders1/570
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/570
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/570
AnxietyPsychiatric disorders1/570
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/570
ColitisGastrointestinal disorders1/570
Most frequent other events
Showing 10 of 180
Most frequent other events
EventBotulinum Toxin, Type A
HeadacheNervous system disorders75/570
Upper respiratory tract infectionInfections and infestations16/570
SinusitisInfections and infestations14/570
NasopharyngitisInfections and infestations13/570
Urinary tract infectionInfections and infestations10/570
HypertensionVascular disorders10/570
ContusionInjury, poisoning and procedural complications9/570
BronchitisInfections and infestations7/570
Eyelid ptosisEye disorders7/570
CoughRespiratory, thoracic and mediastinal disorders7/570

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Botulinum Toxin, Type A
<=18 years0
Between 18 and 65 years519
>=65 years51
Sex: Female, Male
Sex: Female, Male(Participants)Botulinum Toxin, Type A
Female510
Male60
08

Study locations

1 site
  • The Advanced Skin Research Center at Skin Specialists, PC
    Omaha, Nebraska 68144, United States
09

References and documents

Individual participant data

Plan to share: Undecided — Developing a plan

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Oct 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2019, 2 years 4 months after primary completion. A results delay was requested in Feb 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2015
First posted
Apr 29, 2015
Start
May 2015
Primary completionActual
Oct 2016
CompletionActual
Nov 2016
Results delay requested
Feb 1, 2017
Results first posted
Feb 5, 2019
Last update
Apr 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02428608
Lead sponsor
Evolus, Inc.
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Apr 29, 2015
Start date
May 2015
Primary completion
Oct 2016
Completion
Nov 2016
Results posted
Feb 5, 2019
Last update
Apr 24, 2019

Study contacts

Rui Avelar, MD
study director · Evolus, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prabotulinumtoxin A

Start the discussion